Bioavailability and Safety of Dihydroquercetin (Review)

Dihydroquercetin (DHQ) is a bioflavonoid with high antioxidant, capillary-protective, and anti-inflammatory activity. DHQ has previously been used for treating Middle East respiratory syndrome coronavirus (MERS-CoV) infection and is currently considered a potential regulator of oxidative stress as part of COVID-19 multipurpose therapy. DHQ has a high safety profile but low bioavailability that limits its use. Innovative techniques (liposomization, crystal engineering, etc.) can be used to increase its bioavailability. © 2022, Springer Science+Business Media, LLC, part of Springer Nature.

Authors
Orlova S.V. 1 , Tatarinov V.V.2 , Nikitina E.A. 1 , Sheremeta A.V. 1 , Ivlev V.A. 1 , Vasil’ev V.G. 1 , Paliy K.V. 1 , Goryainov S.V. 1
Journal
Pharmaceutical Chemistry Journal
Number of issue
11
Language
English
Pages
1133-1137
Status
Published
Link
External link
DOI
10.1007/s11094-022-02548-8
Volume
55
Year
2022
Organizations
  • 1 Peoples’ Friendship University of Russia (RUDN), 6 Miklukho-Maklaya St., Moscow, 117198, Russian Federation
  • 2 A. P. Vinogradov Institute of Geochemistry, Siberian Branch, Russian Academy of Sciences, 1A Favorskogo St., P. O. Box 9, Irkutsk, 664033, Russian Federation
Keywords
bioavailability; dihydroquercetin; safety; SARS-CoV-2; toxicity
Date of creation
06.07.2022
Date of change
06.07.2022
Short link
https://repository.rudn.ru/en/records/article/record/83870/
Share

Other records